NATCO Pharma Limited (IN:NATCOPHARM)
:NATCOPHARM
NATCOPHARM Stock Chart & Stats
₹893.35
-₹7.80(-0.59%)
At close: 4:00 PM EST
₹893.35
-₹7.80(-0.59%)
Day’s Range― - ―
52-Week Range₹742.80 - ₹1,128.35
Previous CloseN/A
Volume335.92K
Average Volume (3M)59.22K
Market Cap
₹201.40B
Enterprise Value₹202.84B
Total Cash (Recent Filing)₹40.77B
Total Debt (Recent Filing)₹2.61B
Price to Earnings (P/E)26.7
Beta1.00
Next Earnings
Jun 01, 2026EPS Estimate
19.8Next Dividend Ex-DateN/A
Dividend Yield0.57%
Share Statistics
EPS (TTM)8.46
Shares Outstanding179,109,860
10 Day Avg. Volume63,709
30 Day Avg. Volume59,218
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)1.90
Price to Sales (P/S)3.25
P/FCF Ratio10.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)40.12
Revenue Forecast (FY)₹31.85B
Bulls Say, Bears Say
Bulls Say
High Profitability MarginsSustained, very high gross and operating margins indicate durable pricing power, efficient manufacturing and low variable costs in core products. Such margin structure supports reinvestment, funds R&D or partnership launches, and provides cushion against pricing pressure in generics over the coming months.
Strong Balance Sheet & Low LeverageExtremely low leverage and a high equity ratio give NATCO financial flexibility to fund launches, absorb setbacks, or pursue strategic investments without stressing liquidity. A high ROE signals efficient capital allocation that should support long-term shareholder returns and resilience across cycles.
Robust Cash GenerationLarge FCF growth and near‑one-to-one operating cash conversion show high quality earnings and strong cash conversion ability. This durable cash generation can fund capex, support partner launches, reduce reliance on external financing and enable steady investment in specialty generics over the medium term.
Bears Say
Declining Gross Profit & Rising LiabilitiesA falling gross profit trend combined with growing liabilities can erode margin sustainability and reduce financial flexibility over time. If production costs or pricing dynamics continue to pressure gross profit while liabilities rise, NATCO may face constrained cash available for reinvestment and higher financing risk.
Negative EPS GrowthA significant negative EPS growth rate signals per‑share earnings pressure that may reflect mix shifts, higher costs, or one‑offs. Persistent EPS decline can limit capacity to fund growth internally and weakens comparisons versus peers, warranting monitoring of underlying operational drivers and recovery timelines.
Dependence On Milestones & PartnershipsMaterial reliance on partner launches, milestone payments and licensing creates revenue timing risk and episodic earnings. Such structural dependence can produce volatility in cash flow and growth visibility, and success depends on partner execution and regulatory approvals in regulated markets over the medium term.
NATCO Pharma Limited News
NATCOPHARM FAQ
What was NATCO Pharma Limited’s price range in the past 12 months?
NATCO Pharma Limited lowest stock price was ₹742.80 and its highest was ₹1128.35 in the past 12 months.
What is NATCO Pharma Limited’s market cap?
NATCO Pharma Limited’s market cap is ₹201.40B.
When is NATCO Pharma Limited’s upcoming earnings report date?
NATCO Pharma Limited’s upcoming earnings report date is Jun 01, 2026 which is in 52 days.
How were NATCO Pharma Limited’s earnings last quarter?
NATCO Pharma Limited released its earnings results on Feb 12, 2026. The company reported ₹8.46 earnings per share for the quarter, beating the consensus estimate of ₹5.267 by ₹3.193.
Is NATCO Pharma Limited overvalued?
According to Wall Street analysts NATCO Pharma Limited’s price is currently Overvalued.
Does NATCO Pharma Limited pay dividends?
NATCO Pharma Limited pays a Quarterly dividend of ₹1.5 which represents an annual dividend yield of 0.57%. See more information on NATCO Pharma Limited dividends here
What is NATCO Pharma Limited’s EPS estimate?
NATCO Pharma Limited’s EPS estimate is 19.8.
How many shares outstanding does NATCO Pharma Limited have?
NATCO Pharma Limited has 179,109,860 shares outstanding.
What happened to NATCO Pharma Limited’s price movement after its last earnings report?
NATCO Pharma Limited reported an EPS of ₹8.46 in its last earnings report, beating expectations of ₹5.267. Following the earnings report the stock price went down -1.275%.
Which hedge fund is a major shareholder of NATCO Pharma Limited?
Currently, no hedge funds are holding shares in IN:NATCOPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NATCO Pharma Limited
NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina and CHF. The company markets its products in approximately 40 countries, including India, the United States, and internationally. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
Technical Analysis
Glenmark Pharmaceuticals Limited
―
―
Jubilant Pharmova Limited
―
Marksans Pharma Limited
―
Rainbow Childrens Medicare Limited
―